Dr Reddy's hits record high on migraine drug launch in US

Shares in Dr Reddy's Laboratories rose as much as 2.1 percent to a record high on growing hopes about its U.S. business.

The drug maker said late on Tuesday that it launched Sumatriptan injection, used for migraine, for U.S. markets.

Separately, Macquarie upgraded its price target for Dr. Reddy's shares to 3,325 rupees from 3,200 rupees, saying its U.S. business was "significantly under appreciated by the street."

The ramp-up of key products in the United States, including planned launches in fiscal 2015, would help boost sales, Macquarie added.

Shares in the company were up 1.8 percent at 1:18 p.m.

The gains come in contrast to rivals such as Ranbaxy Laboratories Ltd, which has slumped 21 percent since January 11 because of U.S. regulatory issues. In contrast, Dr. Reddy's has gained 5.6 percent during the same period.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The world is moving away from fast food like never before

    Despite spending $1.8 billion every year on worldwide advertising and promotion, McDonald’s sales are plummeting.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schoettli

It’s time for Japan to step out of its shell

The execution of a Japanese hostage by ISIS has sho­cked ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Bubbles Sabharwal

Truth about truth

The question to ponder is, “is it the truth because ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture